证券日报网讯 9月16日晚间，亿帆医药发布公告称，公司全资子公司合肥亿帆生物制药有限公司于2025 年9月15日收到国家药品监督管理局核准签发的注射用硫酸艾沙康唑《药品注册证书》。 （文章来源：证券日报） ...

格隆汇9月16日丨亿帆医药(002019.SZ)公布，公司全资子公司合肥亿帆生物制药有限公司于2025年9月 15日收到国家药品监督管理局核准签发的注射用硫酸艾沙康唑《药品注册证书》。注射用硫酸艾沙康唑 为抗感染药物。适用于治疗成人患者下列感染：侵袭性曲霉病、侵袭性毛霉病。 ...

亿帆医药9月16日晚间公告，公司全资子公司合肥亿帆生物制药有限公司获得国家药品监督管理局核准 签发的注射用硫酸艾沙康唑《药品注册证书》。注射用硫酸艾沙康唑为抗感染药物，适用于治疗成人患 者下列感染：侵袭性曲霉病、侵袭性毛霉病。截至本报告披露日，除本公司外，中国境内注射用硫酸艾 沙康唑有9家企业获批上市，另有多家企业处于仿制药报产审评中。截至本报告披露日，公司对注射用 硫酸艾沙康唑的研发投入约789.72万元。 ...

亿帆医药（002019）(002019.SZ)公告，公司全资子公司合肥亿帆生物制药有限公司于2025年9月15日收 到国家药品监督管理局核准签发的注射用硫酸艾沙康唑《药品注册证书》。注射用硫酸艾沙康唑为抗感 染药物，适用于治疗成人患者下列感染：侵袭性曲霉病、侵袭性毛霉病。 ...

智通财经APP讯，亿帆医药(002019.SZ)公告，公司全资子公司合肥亿帆生物制药有限公司于2025年9月 15日收到国家药品监督管理局核准签发的注射用硫酸艾沙康唑《药品注册证书》。注射用硫酸艾沙康唑 为抗感染药物，适用于治疗成人患者下列感染：侵袭性曲霉病、侵袭性毛霉病。 ...

Group 1 - The core point of the article is that Yifan Pharmaceutical (002019) announced the approval of its subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. for the injection of Sulfate Isavuconazole by the National Medical Products Administration [1] - The approved drug, Sulfate Isavuconazole, is an anti-infective medication [1] - It is indicated for the treatment of adult patients with invasive fungal infections, specifically invasive aspergillosis and invasive mucormycosis [1]

Group 1 - Huazhong Securities has been approved to issue subordinate corporate bonds with a total face value of no more than 10 billion yuan [1] - Jinbei Automotive plans to invest 240 million yuan to establish an automotive industry investment fund focusing on electrification, intelligence, and low carbon [1] - Linyang Energy is expected to win a bid for a 244 million yuan metering equipment project from Southern Power Grid [1][2] Group 2 - Renfu Pharmaceutical's subsidiary has received drug registration certificates for two products, including a medication for acute hypotension [3][4] - Nanjing Steel plans to distribute a cash dividend of 0.1186 yuan per share [5][6] - Pairui Co. has signed a strategic cooperation agreement with Xi'an Power Electronics Research Institute to develop power devices [7][8] Group 3 - Haixing Electric is expected to win a bid for a 214 million yuan metering equipment project from Southern Power Grid [9][10] - Kuangda Technology is planning a change in control, leading to a continued suspension of its stock [11][12] - Samsung Medical is expected to win a bid for a 274 million yuan metering equipment project from Southern Power Grid [13][14] Group 4 - Jiukang Bio has obtained a medical device registration certificate for a specific diagnostic kit [15][16] - Hechuan Technology's minority shareholder plans to transfer a 13% stake in a subsidiary [17][18] - DiAo Micro has launched a new eUSB2 repeater product for various electronic applications [19][20] Group 5 - David Medical's electric surgical table registration application has been accepted [21][22] - Hangxin Technology plans to apply for a total of 280 million yuan in bank credit [23][24] - Liyuan Technology's non-independent director has resigned [25][26] Group 6 - Ningbo Construction's subsidiary has won a construction project bid worth 729 million yuan [27][28] - Huaren Pharmaceutical's subsidiary has received approval for a raw material drug [29][30] - Suwen Electric plans to distribute a cash dividend of 1 yuan per 10 shares [31][32] Group 7 - Solar Energy has received 1.692 billion yuan in renewable energy subsidies [33][34] - Wangli Security has obtained a patent for a new lock structure [35][36] - Zhejiang Energy's vice chairman has resigned due to age reasons [37][38] Group 8 - Beilu Pharmaceutical's subsidiary has passed GMP certification in Brazil [39][40] - Zhejiang Communications has a subsidiary that is expected to win a highway project bid [41][42] - Xinzhi Group has received a government subsidy of 11.1978 million yuan [43][44] Group 9 - Dong'an Power's engine sales in August increased by 3.44% year-on-year [45][46] - Baiyun Mountain's subsidiary has passed the consistency evaluation for two generic drugs [47][48] - Yipin Hong's subsidiary has received a drug registration certificate for a specific injection [49][50] Group 10 - Far East Holdings' subsidiary has won multiple contracts totaling 1.689 billion yuan [51][52] - Good Housekeeping's shareholder plans to reduce holdings by up to 3.5 million shares [53][54] - Guanghong Technology's shareholders have set a transfer price of 23.33 yuan per share [55][56] Group 11 - Keli Sensor plans to acquire 45% of Huahong Technology's shares for 122 million yuan [57][58] - Jianmin Group's furosemide oral solution has been approved for market launch [59][60] - Jinghua Laser's directors plan to reduce their holdings by up to 143,420 shares [61][62] Group 12 - Zhuyue Group is planning a share transfer that will change its controlling shareholder [63][64] - Terid has pre-bid for two projects totaling approximately 698 million yuan [65][66] - Zhonghuan Hailu is planning a change in control, leading to a continued suspension of its stock and convertible bonds [67][68] Group 13 - Great Wall Motors reported August sales of 115,600 vehicles, a year-on-year increase of 22.33% [69][70] - Guizhou Tire's controlling shareholder has committed not to reduce holdings for 12 months [71][72] - San Da Membrane's shareholder plans to reduce holdings by up to 1% of the company's shares [73][74] Group 14 - Chint Electric has decided to terminate the spin-off of its subsidiary for listing [75][76] - Jusaylong's shareholder plans to reduce holdings by up to 1% of the company's shares [77][78]

注射用硫酸艾沙康唑适应症为：主要用于治疗成人患者下列感染：侵袭性曲霉病；侵袭性毛霉病。注射 用硫酸艾沙康唑是国家医保乙类产品。公司获批的注射用硫酸艾沙康唑是以化学药品4类申报注册，视 同通过一致性评价。根据米内网数据，2024年注射用硫酸艾沙康唑在中国城市和县级公立医院的销售规 模约为22,505万元人民币。 格隆汇9月1日丨一品红(300723.SZ)公布，公司全资子公司广州一品红制药有限公司于近日收到国家药 品监督管理局核准签发的关于注射用硫酸艾沙康唑的《药品注册证书》。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the injection of Sulfate Isavuconazole, marking a significant step in enhancing its product pipeline and competitiveness in the anti-infection sector [1] Company Summary - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has obtained the drug registration certificate for injectable Sulfate Isavuconazole [1] - The approved indication for injectable Sulfate Isavuconazole is primarily for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis [1] - This approval allows the company to sell this specific drug in the domestic market, thereby enriching its product offerings [1]

Core Viewpoint - The company Yipinhong (300723) has received approval from the National Medical Products Administration for the drug "Injectable Sulfate of Isavuconazole," which is primarily used to treat invasive aspergillosis and mucormycosis infections in adult patients [1] Group 1 - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., is responsible for the newly approved drug [1] - The approval of Injectable Sulfate of Isavuconazole marks a significant milestone for the company in expanding its pharmaceutical product offerings [1] - The drug targets serious fungal infections, indicating a strategic focus on addressing critical healthcare needs [1]